期刊
ACS MEDICINAL CHEMISTRY LETTERS
卷 10, 期 4, 页码 499-503出版社
AMER CHEMICAL SOC
DOI: 10.1021/acsmedchemlett.8b00532
关键词
cancer; NHERFI; PDZ domain; beta-catenin; drug design; synthesis
资金
- Italian PRIN 2015 [2015FCHJ8E]
- Sapienza University [RP11715C7D1CF0D1]
- AIRC-IG [14236, 17575]
- AFM-Telethon [21025]
- Institute Pasteur Italy
- European Union [675341]
- Marie Curie Actions (MSCA) [675341] Funding Source: Marie Curie Actions (MSCA)
Targeted approaches aiming at modulating NHERFI activity, rather than its overall expression, would be preferred to preserve the normal functions of this versatile protein. We focused our attention on the NHERF1/PDZ1 domain that governs its membrane recruitment/displacement through a transient phosphorylation switch. We herein report the design and synthesis of novel NHERF1 PDZ1 domain inhibitors. These compounds have potential therapeutic value when used in combination with antagonists of beta-catenin to augment apoptotic death of colorectal cancer cells refractory to currently available Wnt/beta-catenin-targeted agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据